Methods of using SNS-595

1. A method for treating leukemia comprising administering to a human patient having leukemia a dose of about 50-110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.

2. The method of claim 1 wherein the dose is 50 mg/m 2 -90 mg/m 2 .

3. The method of claim 1 wherein the dose is 90 mg/m 2 -100 mg/m 2 .

4. The method of claim 1 wherein the does is 100 mg/m 2 -110 mg/m 2 .

5. The method of claim 1 additionally comprising administering to said patient a therapeutically effective dose of a supportive care agent.

6. The method of claim 5 wherein the supportive care agent is an antiemetic.

7. The method of claim 5 wherein the supportive care agent is a hematopoietic agent.

8. A method for treating leukemia comprising: i) administering a dose of about 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a human patient having leukemia; ii) waiting a period of at least one day where the patient is not administered any (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid; iii) administering another dose of about 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to the patient.

9. The method of claim 8 wherein the period is at least 2 days.

10. The method of claim 8 wherein the period is at least 3 days.

11. The method of claim 8 wherein the period is at least 6 days.

12. The method of claim 8 wherein the period is at least 13 days.

13. The method of claim 8 wherein the period is at least 20 days.

14. The method of claim 8 wherein the period is at least 27 days.

15. A method for treating leukemia comprising administering a weekly dose of about 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a human patient having leukemia.

16. A method for treating leukemia comprising administering a dose of about 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid once every three weeks to a human patient having leukemia.

17. A method for treating leukemia comprising a cycle wherein the cycle comprises i) administering a dose of about 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid once every week for three weeks to a human patient having leukemia followed by ii) a period of at least two weeks where no (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid is administered to said patient.

18. A method for treating leukemia comprising administering to a human patient a dose of about 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and one or more doses of a hematopoietic agent.

19. The method of claim 18 wherein the hematopoietic agent is G-CSF.

20. The method of claim 18 wherein the hematopoietic agent is GM-CSF.

21. The method of claim 18 wherein the hematopoietic agent is erythropoietin.

22. The method of claim 18 wherein the hematopoietic agent is erythropoiesis stimulating protein.

23. The method of claim 18 wherein the hematopoietic agent is darbepoietin alfa.

24. The method of claim 8 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

25. The method of claim 8 , wherein the dose is about 90 mg/m 2 -100 mg/m 2 .

26. The method of claim 8 , wherein the dose is about 100 mg/m 2 -110 mg/m 2 .

27. The method of claim 15 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

28. The method of claim 1 wherein the dose is 50 mg/m 2 -60 mg/m 2 .

29. The method of claim 1 wherein the dose is 55 mg/m 2 -65 mg/m 2 .

30. The method of claim 1 wherein the dose is 60 mg/m 2 -70 mg/m 2 .

31. The method of claim 1 wherein the dose is 65 mg/m 2 -75 mg/m 2 .

32. The method of claim 8 further comprising repeating steps ii)-iii) a plurality of times.

33. The method of claim 15 , wherein the dose is about 90 mg/m 2 -100 mg/m 2 .

34. The method of claim 15 , wherein the dose is about 100 mg/m 2 -110 mg/m 2 .

35. The method of claim 16 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

36. The method of claim 16 , wherein the dose is about 90 mg/m 2 -100 mg/m 2 .

37. The method of claim 16 , wherein the dose is about 100 mg/m 2 -110 mg/m 2 .

38. The method of claim 17 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

39. The method of claim 17 , wherein the dose is about 90 mg/m 2 -100 mg/m 2 .

40. The method of claim 17 , wherein the dose is about 100 mg/m 2 -110 mg/m 2 .

41. The method of claim 18 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

42. The method of claim 18 , wherein the dose is about 90 mg/m 2 -100 mg/m 2 .

43. The method of claim 18 , wherein the dose is about 100 mg/m 2 -110 mg/m 2 .